Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
BNXT.CNthis companyBioNxt Solutions Inc.	CA$0.26	-10.76×	-8.07×	0×	-13.49×	-121.0%	0.0%	0.0%	0.0%	75.0%	172.2%	-6.9%	-0.63×	-0.98×	-4.2×	0.05×	0.0%	3	-88.15	2	C
BETR.CNBetterLife Pharma Inc.	CA$0.21	-4.9×	-0.75×	0×	-4.53×	-113.2%	0.0%	0.0%	0.0%	15.3%	32.4%	-8.6%	-0.09×	-0.49×	-7.8×	0.03×	0.0%	3	-83.43	2	C
CYBN.NECybin Inc.	CA$12.78	-1.59×	1.01×	0×	-0.54×	-62.3%	0.0%	0.0%	0.0%	-63.2%	-60.9%	-57.1%	0×	1.11×	-48.88×	9.52×	0.0%	3	8.63	2	C
DOSE.CNRapid Dose Therapeutics Corp.	CA$0.10	-5.88×	-2.78×	7.19×	-15.23×	-398.4%	-34.5%	-78.3%	-122.2%	47.2%	117.1%	-1.4%	-0.74×	-3.2×	-1.78×	0.04×	0.0%	3	-27.84	2	C
INNO.CNInnoCan Pharma Corporation	CA$1.82	-19.52×	3.9×	0.82×	123.74×	-83202.5%	89.9%	-4.7%	-4.2%	-20.1%	54.9%	2.2%	0.17×	-44.28×	-418.33×	7.7×	0.0%	3	-0.95	—	—
LOBE.CNLobe Sciences Ltd.	CA$0.04	-1.57×	2.94×	0×	-0.32×	-29.7%	0.0%	0.0%	0.0%	-187.9%	-80.9%	-20.4%	0.12×	1.31×	-7×	3.13×	0.0%	2	-11.09	2	C
Peer median	—	-4.9×	1.01×	0×	-0.54×	-113.2%	0.0%	0.0%	0.0%	-20.1%	32.4%	-8.6%	0×	-0.49×	-7.8×	3.13×	0.0%	3	-11.09	2	—